A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel-group Study with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic-Clonic Seizures

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel-group Study with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized Tonic-Clonic Seizures

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Perampanel (Primary)
  • Indications Tonic-clonic epilepsy
  • Focus Registrational; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 27 Apr 2018 Results assessing time to pre-randomization monthly seizure count as a potential new clinical endpoint using full analysis set patient population (n=162) from this trial, presented at the 70th Annual Meeting of the American Academy of Neurology.
    • 05 Dec 2017 Results of post hoc analysis of open label extension studies, presented at the 71st Annual Meeting of the American Epilepsy Society.
    • 05 Dec 2017 Results of post hoc analysis presented at the 71st Annual Meeting of the American Epilepsy Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top